Education
Ph.D. in Biochemistry & Medical Genetics, University of Manitoba, Canada, 2007
Current position
Head of Laboratory of Cell Death & Cell Survival (LCDCS), Center for DNA Fingerprinting & Diagnostics (CDFD), Hyderabad
Publications
Research Articles
-
Kavela, S., Shinde, S. R., Ratheesh, R., Viswakalyan, K., Bashyam, M. D., Gowrishankar, S., Vamsy, M., Pattnaik, S., Rao, S., Sastry, R. A., Srinivasulu, M., Chen, J. and Maddika, S. (2013). PNUTS functions as a proto-oncogene by sequestering PTEN. Cancer Res 73(1): 205-214.
-
Jain, M. V., Paczulla, A. M., Klonisch, T., Dimgba, F. N., Rao, S. B., Roberg, K., Schweizer, F., Lengerke, C., Davoodpour, P., Palicharla, V. R., Maddika, S. and Los, M. (2013). Interconnections between apoptotic, autophagic and necrotic pathways: implications for cancer therapy development. J Cell Mol Med 17(1): 12-29.
-
Maddika, S.@, Kavela, S., Rani, N., Palicharla, V. R., Pokorny, J. L., Sarkaria, J. N. and Chen, J. (2011). WWP2 is an E3 ubiquitin ligase for PTEN. Nat Cell Biol 13(6): 728-733. (@ Corresponding author)
-
Maddika, S. and Chen, J. (2009). Protein kinase DYRK2 is a scaffold that facilitates assembly of an E3 ligase. Nat Cell Biol 11(4): 409-419.
-
Maddika, S., Sy, S. M. and Chen, J. (2009). Functional interaction between Chfr and Kif22 controls genomic stability. J Biol Chem 284(19): 12998-13003.
-
Maddika, S., Panigrahi, S., Wiechec, E., Wesselborg, S., Fischer, U., Schulze-Osthoff, K. and Los, M. (2009). Unscheduled Akt-triggered activation of cyclin-dependent kinase 2 as a key effector mechanism of apoptin's anticancer toxicity. Mol Cell Biol 29(5): 1235-1248.
-
Ghavami, S., Eshraghi, M., Kadkhoda, K., Mutawe, M. M., Maddika, S., Bay, G. H., Wesselborg, S., Halayko, A. J., Klonisch, T. and Los, M. (2009). Role of BNIP3 in TNF-induced cell death--TNF upregulates BNIP3 expression. Biochim Biophys Acta 1793(3): 546-560.
-
Maddika, S., Ande, S. R., Wiechec, E., Hansen, L. L., Wesselborg, S. and Los, M. (2008). Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis. J Cell Sci 121(Pt 7): 979-988.
-
Maddika, S., Wiechec, E., Ande, S. R., Poon, I. K., Fischer, U., Wesselborg, S., Jans, D. A., Schulze-Osthoff, K. and Los, M. (2008). Interaction with PI3-kinase contributes to the cytotoxic activity of apoptin. Oncogene 27(21): 3060-3065.
-
Maddika, S., Bay, G. H., Kroczak, T. J., Ande, S. R., Maddika, S., Wiechec, E., Gibson, S. B. and Los, M. (2007). Akt is transferred to the nucleus of cells treated with apoptin, and it participates in apoptin-induced cell death. Cell Prolif 40(6): 835-848.
-
Burek, M.*, Maddika, S.*, Burek, C. J., Daniel, P. T., Schulze-Osthoff, K. and Los, M. (2006). Apoptin-induced cell death is modulated by Bcl-2 family members and is Apaf-1 dependent. Oncogene 25(15): 2213-2222. (* Equal First Authorship)
-
Maddika, S., Booy, E. P., Johar, D., Gibson, S. B., Ghavami, S. and Los, M. (2005). Cancer-specific toxicity of apoptin is independent of death receptors but involves the loss of mitochondrial membrane potential and the release of mitochondrial cell-death mediators by a Nur77-dependent pathway. J Cell Sci 118(Pt 19): 4485-4493.
-
Hashemi, M., Karami-Tehrani, F., Ghavami, S., Maddika, S. and Los, M. (2005). Adenosine and deoxyadenosine induces apoptosis in oestrogen receptor-positive and -negative human breast cancer cells via the intrinsic pathway. Cell Prolif 38(5): 269-285.
-
Barczyk, K., Kreuter, M., Pryjma, J., Booy, E. P., Maddika, S., Ghavami, S., Berdel, W. E., Roth, J. and Los, M. (2005). Serum cytochrome c indicates in vivo apoptosis and can serve as a prognostic marker during cancer therapy. Int J Cancer 116(2): 167-173.
Reviews
-
Ande, S. R., Chen, J. and Maddika, S.# (2009). The ubiquitin pathway: an emerging drug target in cancer therapy. Eur J Pharmacol 625(1-3): 199-205. (#Corresponding author)
-
Los, M., Maddika, S., Erb, B. and Schulze-Osthoff, K. (2009). Switching Akt: from survival signaling to deadly response. Bioessays 31(5): 492-495.
-
Maddika, S., Ande, S. R., Panigrahi, S., Paranjothy, T., Weglarczyk, K., Zuse, A., Eshraghi, M., Manda, K. D., Wiechec, E. and Los, M. (2007). Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat 10(1-2): 13-29.
-
Kroczak, T. J., Baran, J., Pryjma, J., Siedlar, M., Reshedi, I., Hernandez, E., Alberti, E., Maddika, S. and Los, M. (2006). The emerging importance of DNA mapping and other comprehensive screening techniques, as tools to identify new drug targets and as a means of (cancer) therapy personalisation. Expert Opin Ther Targets 10(2): 289-302.
-
Maddika, S., Mendoza, F. J., Hauff, K., Zamzow, C. R., Paranjothy, T. and Los, M. (2006). Cancer-selective therapy of the future: apoptin and its mechanism of action. Cancer Biol Ther 5(1): 10-19.
-
Pour-Jafari, H., Ghavami, S. and Maddika, S. (2005). Mitochondrial Physiology and Toxicity (Mitotoxicity); Importance for the Immune System, Programmed Cell Death and Cancer. Current Medicinal Chemistry-Anti-Inflammatory & Anti-Allergy Agents 4(4): 439-448.
-
Kreuter, M., Langer, C., Kerkhoff, C., Reddanna, P., Kania, A. L., Maddika, S., Chlichlia, K., Bui, T. N. and Los, M. (2004). Stroke, myocardial infarction, acute and chronic inflammatory diseases: caspases and other apoptotic molecules as targets for drug development. Arch Immunol Ther Exp (Warsz) 52(3): 141-155.
Book Chapters
-
Ghavami S., Barczyk K., Maddika S., Pourjafari H., Kroczak T., and Los, M. Monitoring of programmed cell death in vivo: new methods of cancer therapy monitoring. In: Apoptotic pathways as target for novel therapies in cancer and other diseases. Edited by M. Los & S.B Gibson; Kluwer Academic Press (2004) ISBN 0-387-23384-9.
-
Banerji S., Ande SR., Maddika S., Banerji V., Rashedi I., Owens NW., Zuse A., Schweizer F. and Los M.“Peptides and peptidomimetics as cancer therapy sensitizing agents.” in: Sensitization of Cancer Cells to Chemo/Immuno/Radio Therapy. (2008) edited by: B. Bonavida; Humana Press, Inc. ISBN 1934115290.